Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)
General Information of Drug (ID: DR0103) | ||||||
---|---|---|---|---|---|---|
Drug Name |
Amoxapine
|
|||||
Synonyms |
Amoxan; Amoxapina; Amoxapina [INN-Spanish]; Amoxapinum; Amoxapinum [INN-Latin]; Amoxepine; Ascendin; Asendin; Asendis; Demolox; Desmethylloxapin; Moxadil; amoxapine; 14028-44-5; 2-Chlor-11-(1-piperazinyl)dibenz(b,f)(1,4)oxazepin; 2-Chloro-11-(1-piperazinyl)dibenz(b,f)(1,4)oxazepine; 2-Chloro-11-(1-piperazinyl)dibenz[b,f][1,4]oxazepine; BRN 0832057; C17H16ClN3O; CHEMBL1113; CL 67772; CL-67772; Dibenz[b,f][1,4]oxazepine, 2-chloro-11-(1-piperazinyl)-; EINECS 237-867-1; MFCD00069210; MLS000069371; UNII-R63VQ857OT
|
|||||
Indication | Depression [ICD11: 6A71] | Approved | [1] | |||
Structure | ||||||
3D MOL | 2D MOL | |||||
Pharmaceutical Properties | Molecular Weight | 313.8 | Topological Polar Surface Area | 36.9 | ||
Heavy Atom Count | 22 | Rotatable Bond Count | 1 | |||
Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 3 | |||
Cross-matching ID |
|
|||||
The Metabolic Roadmap of This Drug | |||||
---|---|---|---|---|---|
The Full List of Drug Metabolites (DM) of This Drug | ||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
The Full List of Metabolic Reaction (MR) of This Drug | ||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
||||||||||||||||||||||||||||||||||||||||||||||
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug | ||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.